Blue Owl Capital Holdings LP Invests $5.16 Million in Immix Biopharma, Inc. $IMMX

Blue Owl Capital Holdings LP purchased a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 986,240 shares of the company’s stock, valued at approximately $5,158,000. Immix Biopharma accounts for approximately 0.4% of Blue Owl Capital Holdings LP’s holdings, making the stock its 21st largest position.

A number of other large investors have also made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Immix Biopharma by 4.5% during the third quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock worth $1,526,000 after purchasing an additional 31,625 shares in the last quarter. Susquehanna International Group LLP increased its position in shares of Immix Biopharma by 78.8% during the third quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock worth $190,000 after purchasing an additional 40,032 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Immix Biopharma during the third quarter worth $188,000. United Capital Financial Advisors LLC acquired a new position in shares of Immix Biopharma during the third quarter worth $148,000. Finally, Imprint Wealth LLC acquired a new position in shares of Immix Biopharma during the third quarter worth $141,000. 11.26% of the stock is owned by institutional investors and hedge funds.

Immix Biopharma Stock Performance

NASDAQ:IMMX opened at $8.78 on Monday. Immix Biopharma, Inc. has a one year low of $1.87 and a one year high of $11.61. The firm has a market cap of $477.73 million, a price-to-earnings ratio of -9.54 and a beta of 0.12. The firm’s fifty day moving average is $9.46 and its two-hundred day moving average is $7.12.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01. As a group, equities research analysts predict that Immix Biopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on IMMX. Wall Street Zen downgraded Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Citizens Jmp reissued a “market outperform” rating and issued a $23.00 target price on shares of Immix Biopharma in a research report on Friday, March 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research report on Tuesday, April 21st. Morgan Stanley began coverage on Immix Biopharma in a research report on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 target price on the stock. Finally, HC Wainwright upped their target price on Immix Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Friday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Immix Biopharma has a consensus rating of “Moderate Buy” and an average target price of $19.50.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.